RT Journal Article
SR Electronic
T1 SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.14.21267772
DO 10.1101/2021.12.14.21267772
A1 Anupriya Aggarwal
A1 Alberto Ospina Stella
A1 Gregory Walker
A1 Anouschka Akerman
A1 Vanessa Milogiannakis
A1 Fabienne Brilot
A1 Supavadee Amatayakul-Chantler
A1 Nathan Roth
A1 Germano Coppola
A1 Peter Schofield
A1 Jennifer Jackson
A1 Jake Y. Henry
A1 Ohan Mazigi
A1 David Langley
A1 Yonghui Lu
A1 Charles Forster
A1 Samantha McAllery
A1 Vennila Mathivanan
A1 Christina Fichter
A1 Alexandra Carey Hoppe
A1 Mee Ling Munier
A1 Hans-Martin Jack
A1 Deborah Cromer
A1 David Darley
A1 Gail Matthews
A1 Daniel Christ
A1 David Khoury
A1 Miles Davenport
A1 William Rawlinson
A1 Anthony D. Kelleher
A1 Stuart Turville
YR 2021
UL http://medrxiv.org/content/early/2021/12/15/2021.12.14.21267772.abstract
AB Genetically distinct viral variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been recorded since January 2020. Over this time global vaccine programs have been introduced, contributing to lowered COVID-19 hospitalisation and mortality rates, particularly in the first world. In late 2021, the Omicron (B.1.1.529) virus variant emerged, with significant genetic differences and clinical effects from other variants of concern (VOC). This variant demonstrated higher numbers of polymorphisms in the gene encoding the Spike (S) protein, and there has been displacement of the dominant Delta variant. We assessed the impact of Omicron infection on the ability of: serum from vaccinated and / or previously infected individuals; concentrated human IgG from plasma donors, and licensed monoclonal antibody therapies to neutralise virus in vitro. There was a 17 to 22-fold reduction in neutralisation titres across all donors who had a detectable neutralising antibody titre to the Omicron variant. Concentrated pooled human IgG from convalescent and vaccinated donors had greater breadth of neutralisation, although the potency was still reduced 16-fold. Of all therapeutic antibodies tested, significant neutralisation of the Omicron variant was only observed for Sotrovimab, with other monoclonal antibodies unable to neutralise Omicron in vitro. These results have implications for ongoing therapy of individuals infected with the Omicron variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by The University of New South Wales Rapid Response grant (Australia, ADK), the Medical Research Future Fund COVID-19 grant (MRFF2005760, SGT), Medical Research Future Fund Antiviral Development Call grant (DC), Medical Research Future Fund COVID-19 grant (MRFF2001684, ADK), the New South Wales Health COVID-19 Research Grants Round 2 (FB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human serum samples were obtained with written informed consent from the participants under ethics approvals of St Vincent's Hospital Ethics Committee 2020/ETH00964 and Westmead Hospital Ethics Committee 2020/ETH02068).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript